VolitionRx (NYSE American: VNRX) is trying to forge a similarly early path to the one Guardant Health (NASDAQ: GH), Exact Sciences (NASDAQ: EXAS), and Natera (NASDAQ: NTRA) walked years ago — three blood-based cancer diagnostics platforms that compounded into $10B+ public companies. Same scientific class. Much earlier stage. Outcomes are not guaranteed.
94% Stage I, 96% Stage II — Early Cancer Detection.
The hardest problem in early cancer detection has always been the same: cancer DNA hides in blood at a vanishingly low ratio. Find it reliably without false positives, and you’ve cleared the gate that keeps most multi-cancer screening tests stuck in research mode.
In its blinded Capture-Seq™ validation cohort, Volition reported 94% sensitivity for Stage I and 96% sensitivity for Stage II cancers, at 95% specificity, on top of an enrichment step that delivers 180-fold concentration of cancer DNA at 99% purity. The cohort: 81 subjects — 59 cancer patients (lung and colorectal) and 22 healthy controls. Across all stages, sensitivity ran 93%.
Volition has stated Capture-Seq™ targets a $36 billion TAM spanning multi-cancer early detection (MCED) and minimal residual disease (MRD) — the same diagnostic categories where Abbott just paid $21 billion for Exact Sciences and Roche paid up to $595 million for SAGA Diagnostics.
94%
Sensitivity for Stage I cancers
96%
Sensitivity for Stage II cancers
95%
Specificity across the validation cohort
$36B
TAM — MCED + MRD (company estimate)
Capture-Seq™ Detection by Stage
Cohort Breakdown
Colorectal cancer (45) 56%
Lung cancer (14) 17%
Healthy controls (22) 27%
Closest Science Match
What Cologuard Did. What VNRX Could Do.
The closest scientific analog to VolitionRx’s Capture-Seq™ isn’t one of the liquid-biopsy giants. It’s Cologuard — a cancer-detection test reading epigenetic DNA methylation markers (LASS4, LRRC4, PPP2R5C, co-discovered with Mayo Clinic). Cologuard reads cancer DNA from stool. Capture-Seq™ enriches and reads cancer DNA from blood. Same biological signal class. Comparable clinical performance tier. Different sample types — and very different stage on the commercial curve. (Capture-Seq™ is a separate innovation from Volition’s broader Nu.Q® platform, which spans cancer, sepsis, veterinary, and pharma research products.)
Cologuard Plus — Approved Standard
Exact Sciences · NASDAQ: EXAS
95%
Cologuard Plus colorectal cancer sensitivity at 94% specificity (FDA-approved Oct 4, 2024)
Sample: Stool
Mechanism: Epigenetic DNA methylation at LASS4, LRRC4, PPP2R5C (co-discovered with Mayo Clinic) + KRAS + FIT
Revenue: $1.5M (Q4 2014) → $3.25B (2025)
Outcome: Abbott acquired at $21B EV / $105 per share cash, March 23, 2026
Cultural proof: Cologuard runs prime-time TV ads — household name for routine cancer screening
Same Science Class
Capture-Seq™ — The Cancer-Detection Innovation
VolitionRx · NYSE American: VNRX
94 / 96%
Capture-Seq Stage I / Stage II cancer sensitivity at 95% specificity (81-subject blinded cohort)
Sample: Blood
Mechanism: Capture-Seq™ enriches circulating tumor DNA (ctDNA) 180× at 99% purity for sequencing — addressing the core challenge that ctDNA hides in blood at vanishingly low ratios.
Validation: Independent Mayo Clinic peer-review in Shock (674 trauma patients) — via Volition’s broader Nu.Q® platform.
Revenue: $1.7M FY2025 (+40% YoY, Nu.Q® Vet + Discover) — comparable starting zone to early Cologuard.
Status: Capture-Seq™ pre-commercial. Working to forge a similarly early path. No guarantee of a comparable outcome.
Cologuard Plus methylation marker set (LASS4, LRRC4, PPP2R5C, ZDHHC1 reference) per FDA Summary of Safety and Effectiveness Data (P230043) and Exact Sciences press release dated October 4, 2024. Performance data per the BLUE-C pivotal study. Comparison provided for industry-context purposes only and does not imply equivalent regulatory status, market adoption, or future valuation. Cologuard Plus is approved for colorectal cancer screening; VolitionRx Capture-Seq™ is in pre-commercialization research-use status.
Three Lessons
Same DNA. Different Stage.
Three reference points on a similar arc — three blood-based diagnostics platforms that compounded into $10B+ public companies. Exact Sciences took epigenetic methylation cancer markers from a single test to a $21 billion takeout. Guardant Health turned blood-based oncology into a category. Natera expanded a single platform across cancer, women’s health, organ health, and transplant monitoring. Each one once stood at an earlier-stage point comparable to where VolitionRx sits today. VolitionRx is trying to forge a similarly early path. Outcomes are not guaranteed.
The Cologuard Arc — Closest Science Match
Exact Sciences NASDAQ: EXAS · Acquired by Abbott $21B
$1.5M → $3.25B
Cologuard launched Q4 2014 with ~4,000 tests and $1.5M in revenue; 2025 revenue: $3.25B.
Cologuard Plus (FDA-approved Oct 2024) reads epigenetic DNA methylation markers co-discovered with Mayo Clinic — a comparable scientific class to VolitionRx’s Capture-Seq™ (the cancer-DNA enrichment innovation).
Abbott closed the takeout at $105/share, $21B EV, March 23, 2026.
VNRX comparable: first clinical certification sale of Nu.Q® Cancer (lung cancer assay) at Hospices Civils de Lyon, Nov 2025 — a similar early commercial milestone, eleven years offset. Past results for Exact are not predictive of future results for VNRX.
Blood-Based Oncology Pioneer
Guardant Health NASDAQ: GH
$90.6M → ~$982M
2018 revenue $90.6M → 2025 revenue ~$982M; market cap ~$10B.
Built the public-market identity of blood-based liquid biopsy — the foundational thesis behind every blood-based oncology company that followed.
Guardant operates on circulating tumor DNA. VNRX operates on circulating nucleosomes — a different biomarker class within a comparable biological framework.
VNRX scope is broader: cancer, sepsis, immune response, veterinary diagnostics. Whether VNRX achieves comparable scale is not guaranteed.
Platform Expansion Across Verticals
Natera NASDAQ: NTRA
$190M → $2.3B
2015 revenue $190M → 2025 revenue $2.3B; market cap ~$26.3B.
Began in cell-free DNA for women’s health, then expanded into oncology, organ health, and transplant monitoring.
The textbook platform-expansion story: one core science, multiple commercial paths.
Nu.Q® is structured along comparable lines: cancer, sepsis, veterinary, and pharma research all running off the same nucleosome biology — VNRX is trying to forge a similarly early multi-vertical path; success is not guaranteed.
VolitionRx remains an earlier-stage diagnostics company. Comparisons to Guardant Health, Exact Sciences, and Natera are for industry-context purposes only and do not imply equivalent regulatory status, revenue scale, market adoption, or future valuation.
The $23M Vet Signal
A $23 Million Vet Signal That Most Biotech Investors Overlook.
Most biotech investors auto-discount the veterinary line. They shouldn’t, because the vet business is doing the de-risking work — proving the platform is licensable, milestone-able, and globally distributable today, not in some future scenario.
Today — Veterinary, Commercial
Veterinary Cancer Testing
$23M
$10M upfront + $13M achieved milestones · up to $5M pending feline lymphoma trigger
VolitionRx has received $23 million in upfront and milestone payments under its exclusive agreement with Heska, an Antech company, for in-hospital access to the Nu.Q® Vet Cancer Test. An additional $5 million milestone remains pending — tied to a feline lymphoma commercialization or peer-reviewed publication trigger. IDEXX launched the IDEXX Nu.Q® Canine Cancer Test in January 2023.
20+ Countries
Antech/Heska · IDEXX · Fujifilm Vet Japan (1,700+ Hospitals) · Vita Genomics · DNA Tech · Nationwide · VPG
Same Science
Tomorrow — Human Pathway
Human Diagnostics — Larger TAM
$36B
Multi-Cancer Early Detection (MCED) + Minimal Residual Disease (MRD) · company estimate
Cancer
Sepsis
Disease Monitoring
Point-of-Care
If a veterinary cancer testing agreement can generate $23 million in upfront and milestone payments, the potential scale of human diagnostics — where the addressable markets in cancer, sepsis, and disease monitoring are significantly larger — deserves a closer look.
Active Partner Footprint
Werfen · Hologic · Mayo Clinic · Hospices Civils de Lyon
Veterinary success does not guarantee human commercial success, but it gives investors a real-world signal: Volition’s platform has already attracted commercial partners and milestone economics.
Sector Re-Pricing
What Major Acquirers Are Paying for Cancer Diagnostics.
What the major acquirers have actually written checks for in the last 24 months — set against where Volition trades today.
Jun 2023
Quest Diagnostics →Haystack Oncology
$300M + $150M earnouts
MRD, pre-commercial liquid biopsy.
Jul 2024
Thermo Fisher →Olink
$3.1B · ≈15.5× rev
Proteomics platform, closed.
Mar 23, 2026
Abbott →Exact Sciences
$21B EV
Cancer screening / MCED. Closed at $105/share cash.
Apr 16, 2026
Roche →SAGA Diagnostics
Up to $595M
MRD, announced.
VNRX Market Cap Today
~$26 Million
vs.
What Abbott Just Paid for One Franchise
$21 Billion
Volition targets the same MCED + MRD categories and has publicly stated it is in active discussions with ~10 leading diagnostic and liquid-biopsy companies about potential licensing (Feb 2026 company update). A licensing deal is not a takeout, and “active discussions” are not signed contracts — but the major acquirers are no longer watching from the sidelines.
For industry-context purposes only — comparisons do not imply equivalent regulatory status, scale, or future valuation.
The Setup
The Setup Investors Look For.
The biggest diagnostics winners often share the same DNA: Validated science. Commercial pathway. Scalable testing category. Large unmet market. Guardant Health scaled blood-based oncology liquid biopsy into a ~$10B public company. Exact Sciences scaled non-invasive cancer screening into billions in annual revenue and a $21B Abbott takeout. Natera expanded cell-free DNA testing across women’s health, oncology, and organ health into a ~$26.3B platform. Different molecules, different starting wedges, the same four-pillar shape underneath.
Validated Science
Commercial Pathway
Scalable Category
Large Unmet Market
Guardant Health
Exact Sciences
Natera
VolitionRx
94% Stage I, 96% Stage II sensitivity (Capture-Seq, 81-subject cohort)
$23M received (Antech/Heska), 20+ countries
5 platform branches, dated partners on each
$36B MCED + MRD (company estimate)
VolitionRx is earlier-stage, but it is building around the same investor-relevant ingredients larger diagnostics winners share. None of the below translates into a guaranteed outcome — but each piece is on the page today, with a date and a partner attached.
Validated science: 94% Stage I, 96% Stage II sensitivity at 95% specificity; 180× enrichment at 99% purity (Capture-Seq™ 81-subject blinded cohort).
Commercial pathway: $23M cash-positive on the veterinary side already (Antech/Heska milestone payments).
Scalable category: five branches off one core science (cancer, sepsis, vet, pharma, point-of-care) — each with a date and a partner.
Large unmet markets: $36B MCED + MRD (company estimate), plus sepsis (April 29, 2026 finger-prick lateral flow prototype), plus immune response, plus pharma research.
Why now: before the market decides whether Nu.Q® and Capture-Seq™ can move from promising technologies to scaled diagnostics company.
Same scientific class. Earlier stage. VolitionRx is trying to forge a similarly early path — not guaranteed to succeed.
Stay on the Tape
Stay on the Tape.
The catalyst calendar runs through 2026. We send updates only on the material moments — no weekly newsletters, no marketing churn.
By submitting you consent to receive email updates from The Biotech Catalyst Report about VolitionRx (NYSE American: VNRX). Unsubscribe anytime. No marketing churn.